Recruiting
Quizartinib
Phase 3 Hematology
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Trial #: NCT06578247
Recruiting
Quizartinib
Phase 2 Hematology
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Trial #: NCT06824168
Recruiting
Quizartinib
Phase 1 Hematology
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Trial #: NCT06740799

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.